Lilly to open diabetes research center in China
Indianapolis-based Eli Lilly and Co. plans to open a diabetes research center in China, the drugmaker said Tuesday, citing the high incidence of the disease there.
Life Science & Biotech
Articles
Indiana’s life sciences industry sees trouble ahead
Indiana’s life sciences industry has weathered the recession relatively well, but Eli Lilly’s struggles and tight capital markets could threaten the future.
Indiana life sciences sector copes with shrinking VC pool
Venture funds nationwide crested at $100 billion in 2000, but that number last year had drooped to $18 billion.
Eli Lilly will have to beat odds to meet drug-rollout goals
Eli Lilly and Co. executives have said repeatedly that the company’s bulging pipeline will produce two new drugs per year, beginning in 2013. But only three times in the past six decades has Lilly been able to launch two or more new drugs in back-to-back years.
Dow Agro sales climb, but profit suffers
Indianapolis-based Dow AgroSciences improved revenue during the third quarter thanks to a 26-percent increase in volume, but it still recorded a loss for the period.
Former IU tech-transfer chief: State isn’t competitive enough
Mark Long was president of the Indiana University Research & Technology Corp., which was responsible for the university’s tech transfer, before launching a consulting firm, Long Performance Advisors, in 2008.
BioCrossroads helping laid-off life sciences workers land safely
Indiana firms have dismissed more than 1,400 life science workers over the last two years. Now BioCrossroads has launched a website that aims to keep that talent in the state.
FDA demands more tests on new Lilly diabetes drug
Eli Lilly and Co. will have to wait at least 18 months and conduct more studies before it wins market approval of a once-weekly version of diabetes drug Byetta, a potential billion-dollar drug.
Q&A
Amy Zucker is president of Indianapolis-based Synergy Marketing Group. Her firm was recently hired by Indianapolis-based ImmuneWorks Inc. to use a new website and search engine optimization to help recruit patients for a Phase 1 trial of ImmuneWorks experimental medicine idiopathic pulmonary fibrosis. The Web strategy is a new wrinkle on patient recruitment—in addition to the traditional partnerships with disease specialists at academic medical centers—that Zucker hopes leads to lower costs and faster clinical trials. Phase 1 clinical trials cost nearly $16,000 per patient.
Prosolia Inc. restructures top management
The company, which develops mass spectrometry devices used in the life sciences and industrial chemistry, has a new CEO, among other changes.
Biomet sales rise, but slower than expected
Biomet’s quarterly results are considered an indicator on the state of the orthopedic device industry because it reports results before most of its competitors.
Lilly’s Erbitux shows mixed results in cancer studies
In combination with chemotherapy, the drug failed to help colon-cancer patients in a European trial but did delay the spread of breast cancer in some patients with a certain type of aggressive tumor.
Beckman Coulter plans $18.2M expansion, 100 new jobs
California-based life sciences firm Beckman Coulter Inc. is planning its third local expansion since 2007, investing $18.2 million in its Indianapolis operation and adding as many as 95 jobs here in the next three years.
Community moves to integrate doctors
Community Health now has about 550 physicians, either on its payroll or committed through integration contracts, who have some of their pay hinge on measures of quality and communication. CEO Bryan Mills says the hospital system is looking to add even more.
Dow Agro acquires Colorado seed company
Grand Valley Hybrids has been growing and conditioning hybrid seed corn in the West since 1946.
Appeals court ruling upholds Lilly’s Evista patents
Eli Lilly and Co. won a court ruling Wednesday that blocks plans by Teva Pharmaceutical Industries Ltd. to sell a generic version of the Evista osteoporosis treatment before March 2014.
Local economic espionage case full of intrigue
The government's allegations read like a spy novel: Dr. Ke-xue "John" Huang lands a job at Indianapolis-based Dow AgroSciences and over five years works himself into a position of trust, with access to trade secrets and processes the company has invested $300 million to develop.
Ex-Dow Agro scientist’s espionage indictment unsealed
A federal indictment unsealed Tuesday in Indianapolis charged 45-year-old Ke-xue "John" Huang
with theft and attempted
theft of trade secrets to benefit a foreign government.
Endocyte’s $86M IPO plan a boon for Indiana, investors
Venture capitalists in Indiana and nationally have thrown money at the company with abandon. Local investors include CID Capital,
Clarian Health Ventures and the Indiana Future Fund.
Cancer drug developer Endocyte files for IPO
The company, headquartered at Purdue Research Park, said the number of shares to be offered and their price range have yet
to be determined.